RIVERSIDE — The sale of Merck's Cherokee plant to a Philadelphia-based labor force management company was completed Friday, according to unofficial reports.

Merck (NYSE:MRK) is reportedly looking to expand its U.S. manufacturing presence with a $1 billion facility in Delaware, becoming the latest pharmaceutical company to boost domestic investment as ...

Will Trump tariff plan actually boost U.S. manufacturing? Merck is investing $1 billion to build a U.S. plant in Delaware, in a show of its commitment to domestic manufacturing.

Merck said last week its biggest tariff exposure is through Keytruda and it has enough US inventory for this year. It estimated $200 million in additional costs for the levies implemented to date.

Merck said last week its biggest tariff exposure is through Keytruda and it has enough U.S. inventory for this year. It estimated $200 million in additional costs for the levies implemented to date.

RIVERSIDE — Though Merck is phasing out its Cherokee Plant in Riverside, the company recently acquired a parcel of land adjacent to the plant.

Merck said last week its biggest tariff exposure is through Keytruda and it has enough U.S. inventory for this year. It estimated $200 million in additional costs for the levies implemented to date.

U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it prepares to deal with President Donald Trump's tariffs.